Shioyama Yoshiyuki, Nakamura Katsumasa, Ohga Saiji, Nomoto Satoshi, Sasaki Tomonari, Yamaguchi Toshihiro, Toba Takashi, Yoshitake Tadamasa, Terashima Hiromi, Honda Hiroshi
Department of Clinical Radiology, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka City, Fukuoka 812-8582, Japan.
Jpn J Clin Oncol. 2007 Dec;37(12):918-23. doi: 10.1093/jjco/hym138.
To evaluate the outcome of radiotherapy for recurrent esophageal cancer after surgery and to determine the prognostic factors.
From 1987 through 2002, 82 patients treated with radiotherapy for loco-regional recurrences of esophageal cancer after surgery were retrospectively reviewed. The stage at initial surgery was I in 16, II in 41, III or higher in 24 and unknown in 1. The median size of recurrent tumors was 3.5 cm in diameter. Fifty-two patients were treated with radiotherapy alone, and 30 were treated with radiotherapy combined with chemotherapy. The median total dose of external radiotherapy given was 50.4 Gy in 28 fractions.
The median survival period after recurrence was 7.0 months. The 2- and 5-year overall survival rate for all patients was 22 and 11%, respectively. In univariate analysis, the patients with performance status (PS) = 0-1, or tumor size <3.5 cm, and those treated with total dose >/=50 Gy showed a better survival outcome than each the other groups. The patients with a history of previous radiotherapy showed a poorer survival outcome in univariate analysis than each the other groups. In multivariate analysis, tumor size, PS and radiation dose were independent prognostic factors for overall survival.
The prognosis of patients with post-operative loco-regional recurrence of esophageal cancer is poor. However, a long-term survival may be expected by definitive radiotherapy for the patients with small-size tumors and with a good PS.
评估食管癌术后复发患者的放疗效果并确定预后因素。
回顾性分析1987年至2002年期间82例接受放疗的食管癌术后局部区域复发患者。初次手术时的分期为I期16例,II期41例,III期或更高分期24例,1例分期不明。复发肿瘤的中位大小为直径3.5 cm。52例患者仅接受放疗,30例患者接受放疗联合化疗。外照射的中位总剂量为50.4 Gy,分28次给予。
复发后的中位生存期为7.0个月。所有患者的2年和5年总生存率分别为22%和11%。单因素分析显示,体能状态(PS)=0-1、肿瘤大小<3.5 cm以及接受总剂量≥50 Gy治疗的患者生存结果优于其他组。既往有放疗史的患者在单因素分析中的生存结果比其他组差。多因素分析显示,肿瘤大小、PS和放疗剂量是总生存的独立预后因素。
食管癌术后局部区域复发患者的预后较差。然而,对于肿瘤较小且PS良好的患者,确定性放疗有望实现长期生存。